Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a “cold” immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy. Growing evidence indicates that oncolytic viruses (OVs) act in a multimodal fashion, inducing immunogenic cell death and thereby eliciting robust anticancer immune responses. In this review, we summarize information about OV-mediated immune conversion of the tumor microenvironment. As a case study we focus on the rodent protoparvovirus H-1PV and its dual role as an oncolytic and immune modulatory agent. Potential strategies to improve H-1PV anticancer efficacy are also discussed.
CITATION STYLE
Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A., & Rommelaere, J. (2019). Immune conversion of tumor microenvironment by oncolytic viruses: The protoparvovirus H-1PV case study. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2019.01848
Mendeley helps you to discover research relevant for your work.